肌醇对多囊卵巢综合征女性辅助生殖技术结局的影响：一项随机临床试验研究的系统评价和荟萃分析
The effect of myo-inositol on assisted reproductive technology outcomes in women with polycystic ovarian syndrome: A systematic review and meta-analysis of randomized clinical trial studies.
作者信息
Sene Azadeh Akbari, Saeedzarandi Maryam, Yazdizadeh Maryam, Ghaffari Seyede Razieh, Amjadi Fatemehsadat, Zandieh Zahra, Moradi Yousef
机构信息
Shahid Akbar Abadi Clinical Research Development Unit (ShACRDU), School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Reproductive Sciences and Technology Research Center, Department of Anatomy, Iran University of Medical Sciences, Tehran, Iran.
出版信息
Int J Reprod Biomed. 2025 Jul 29;23(5):353-376. doi: 10.18502/ijrm.v23i5.19260. eCollection 2025 May.
BACKGROUND
Conflicting evidence from clinical trials on the effects of myo-inositol and D-chiro-inositol on assisted reproductive technology (ART) outcomes in women with polycystic ovarian syndrome (PCOS) necessitates a systematic review and meta-analysis.
OBJECTIVE
To evaluate the effect of myo-inositol and D-chiro-inositol on ART outcomes in women with PCOS.
MATERIALS AND METHODS
A comprehensive search was conducted in PubMed, Scopus, Web of Science, EMBASE, ClinicalTrials.gov, and the Cochrane Library for studies published from January 2000-2023. Statistical analyses were performed using STATA version 17.
RESULTS
17 intervention studies were included. myo-inositol/D-chiro-inositol supplementation significantly increased the clinical pregnancy rate (RR: 1.64, 95% CI: 1.25-2.15; I = 13.5%; p = 0.32) and top-grade embryos (RR: 1.12, 95% CI: 1.02-1.23; I = 85.43%; p = 0.0001). However, it was associated with reductions in antral follicle count (WMD: -0.78, 95% CI: -1.07 to -0.49; I = 97.37%; p = 0.001) and anti-Mullerian hormone levels (WMD: -0.46, 95% CI: -0.67 to -0.25; I = 91.95%; p = 0.001).
CONCLUSION
This meta-analysis provides reliable evidence on the effects of myo-inositol/D-chiro-inositol on fertility and ovarian function in women with PCOS undergoing ART.
背景
关于肌醇和D-手性肌醇对多囊卵巢综合征（PCOS）女性辅助生殖技术（ART）结局影响的临床试验证据相互矛盾，因此有必要进行系统评价和荟萃分析。
目的
评估肌醇和D-手性肌醇对PCOS女性ART结局的影响。
材料与方法
在PubMed、Scopus、科学网、EMBASE、ClinicalTrials.gov和Cochrane图书馆中全面检索2000年1月至2023年发表的研究。使用STATA 17版进行统计分析。
结果
纳入17项干预研究。补充肌醇/D-手性肌醇显著提高了临床妊娠率（RR：1.64，95%CI：1.25 - 2.15；I² = 13.5%；p = 0.32）和优质胚胎率（RR：1.12，95%CI：1.02 - 1.23；I² = 85.43%；p = 0.0001）。然而，它与窦卵泡计数减少（WMD：-0.78，95%CI：-1.07至-0.49；I² = 97.37%；p = 0.001）和抗苗勒管激素水平降低（WMD：-0.46，95%CI：-0.67至-0.25；I² = 91.95%；p = 0.001）有关。
结论
这项荟萃分析为肌醇/D-手性肌醇对接受ART的PCOS女性生育能力和卵巢功能的影响提供了可靠证据。
Zotero 插件